Drug Trial Radar · NCT07950332
A Phase II Clinical Study of HRS-7172 as Monotherapy or in Combination With Anti-Tumor Therapy in Participants With Advanced Lung Cancer to Evaluate Safety, Tolerability, and Efficacy
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Dec 1, 2028
Study completion Dec 30, 2029
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-7172 combined with other antitumor therapies in subjects with locally advanced or metastatic non-small cell lung cancer; Evaluate the pharmacokinetic (PK) characteristics of HRS-7172 and other efficacy endpoints for the treatment of locally advanced or metastatic non-small cell lung cancer.
Conditions
- Lung Cancer
Interventions
HRS-7172 tabletDrug
HRS-7172 tablet fixed dose
HRS-7172; SHR-4610 ; chemotherapyDrug
HRS-7172 fixed dose+ /SHR-4610 fixed dose± chemotherapy fixed dose
HRS-7172 ; SHR-9839(sc) ; SHR-4610Drug
HRS-7172 fixed dose+SHR-9839(sc) fixed dose b/SHR-4610 fixed dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v6.0)Time frame: 2 month
- Determine dose recommendation (RP2D)Time frame: 6month
- Objective response rate (ORR)Time frame: 1 year
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Zhejiang Tumor Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.